關於 in vitro diagnostic ，我們在網路上蒐集到這些相關的討論、資訊與評價

▍實創國際生技股份有限公司 STRONG BIOTECH CORPORATION

實創生技掌握免疫學、微生物、蛋白質體學等自有技術開發出幽門桿菌體外檢測試劑及相關生技原物料，為全球第一家生產乾濕兩式幽門螺旋桿菌尿素酶檢驗試劑的公司。

HelicotecUT®Plus幽門螺旋桿菌尿素酶快速檢驗試劑為實創生技的乾式試劑，用於檢測胃黏膜上幽門螺旋桿菌產生之尿素酶反應。使用操作方便，排除訓練操作的需求，提供準確靈敏度高的判讀，更能在60分鐘內快速判讀；HelicotecAG® 胃幽門螺旋桿菌抗原快速檢驗試劑採集糞便檢體，無須搭配儀器操作。本檢驗試劑準確靈敏度高，10~20分鐘快速判讀。

Strong Biotech Corp. holds key technologies in fields like immunology, microbiology, proteomics, such as developing Helicobacter pylori (H. pylori) in vitro diagnostic devices and related biotech materials.

The HelicotecUT®Plus paper test is used to detect H. pylori with urease activity during gastric mucosal biopsies. It’s easy to use, eliminating the need to train personnel and offers sensitive and accurate results. Doctors can usually obtain results within an hour.

The HelicotecAG rapid test H. pylori Stool Antigen takes stool samples instead of relying on other instruments for diagnosis. Offering highly sensitive and accurate results, the HelicotecAG rapid test can quickly provide results between 10 to 20 minutes of application.

#台灣國際醫療展 MEDICAL TAIWAN
Oct.15-17, 2020 @ TaiNEX 2

【參觀登記】https://reurl.cc/MvrALK
【參展報名】https://reurl.cc/E7V7Vm-
【Visitor Registration】https://reurl.cc/Oq7z5g
【Booth Application】https://reurl.cc/6lV9j5

#按讚資訊不漏接
Follow us for more innovative products!

不能因為「抗生素」三個字而下定論

困難梭狀桿菌感染(CDI)是由於長期服用抗生素造成腸道菌相改變，使困難梭狀桿菌有機會大量複製且分泌毒素進而造成腸道發炎。科學家現研發出一種新型抗生素 Ramizol，動物實驗證實可有效抑制CDI，在藥物安全性研究中，經連續14天向48隻感染困難梭狀桿菌的大鼠注射高劑量的 Ramizol，沒有產生嚴重的副作用或體重變化，對動物而言是一種耐受性良好的抗生素，未來將有望用於人類CDI治療。

[1]Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis. J Antibiot (Tokyo). (2016)

[2]Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution. Diagnostic Microbiology and Infectious Disease. (2018)

感謝TVBS「世界翻轉中」的專題報導！
安盛的三位創辦人蔡東孟執行長, 陳彥宇技術長及陳階曉醫療長在科技部主辦的「台灣—史丹福醫療器材產品設計之人才培訓計畫」(STB計畫)結識，並在矽谷發明出PixoTest技術，「STB計畫」可說是安盛的搖籃！
如今PixoTest技術已發展出多項產品，不僅血糖，更可用手機檢測排卵，幫助備孕中的伴侶；甚至發展出定點照護系統，讓多項檢測整合於一行動裝置，讓醫療更加無遠弗屆！
我們會更加努力，讓台灣行動醫療技術被世界看見之餘，更可廣納各地人才，發揮最大的價值！
Thank TVBS “Change” show for the interview!
Our three co-founders, Alan Tsai, the CEO, Jerry Chen, the CMO, Carson Chen, the CTO, first met in Stanford-Taiwan Biomedical Fellowship Program (STB) and came up with the idea of PixoTest technology in Silicon Valley. STB program incubated iXensor!
After years of effort, we have developed multiple in vitro diagnostic applications based on the platform of the PixoTest technology, such as blood glucose, ovulation test for women who are trying to conceive, and POCT system integrating HbA1c and Lipid panel tests on mobile devices.
We’ll keep improving ourselves to let the world recognize us and attract more talents to join us!
https://youtu.be/op2WAiEP1H0